Bid Protein and Cervical Cancer Treatment Outcomes
Author Information
Author(s): Green M M L, Hutchison G J, Valentine H R, Fitzmaurice R J, Davidson S E, Hunter R D, Dive C, West C M L, Stratford I J
Primary Institution: University of Manchester
Hypothesis
The expression of the proapoptotic protein Bid is an adverse prognostic factor for radiotherapy outcome in carcinoma of the cervix.
Conclusion
Strong tumour Bid expression is associated with poor outcomes following radiotherapy, particularly in younger patients.
Supporting Evidence
- Strong Bid expression was associated with a patient age less than the median of 52 years.
- High Bid expression correlated with poor metastasis-free survival.
- Multivariate analysis showed Bid expression was a significant prognostic factor for disease-specific survival.
Takeaway
This study found that if a protein called Bid is very active in cervical cancer cells, it can mean the treatment won't work as well, especially for younger patients.
Methodology
Bid expression was assessed using immunohistochemistry in pretreatment archival biopsies from patients, and correlated with clinicopathologic characteristics and treatment outcomes.
Potential Biases
Potential biases may arise from the retrospective nature of the study and the specific treatment protocols used.
Limitations
The study was limited to a specific patient cohort and may not generalize to all cervical cancer patients.
Participant Demographics
Patients had locally advanced squamous cell carcinoma of the cervix, with a median age of 52 years.
Statistical Information
P-Value
0.026
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website